(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 33.2% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Autolus Therapeutics's revenue in 2026 is $117,390,000.On average, 11 Wall Street analysts forecast AUTL's revenue for 2026 to be $39,735,405,597, with the lowest AUTL revenue forecast at $33,595,035,799, and the highest AUTL revenue forecast at $42,774,981,803. On average, 11 Wall Street analysts forecast AUTL's revenue for 2027 to be $52,497,899,390, with the lowest AUTL revenue forecast at $41,603,866,627, and the highest AUTL revenue forecast at $60,434,866,332.
In 2028, AUTL is forecast to generate $75,720,581,005 in revenue, with the lowest revenue forecast at $44,587,548,701 and the highest revenue forecast at $114,303,502,803.